|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenhalgh J, Dwan K, Boland A, Bates V,
Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of
advanced epidermal growth factor receptor (EGFR) mutation positive
non-squamous non-small cell lung cancer. Cochrane Database Syst Rev
CD010383. 2016. View Article : Google Scholar
|
|
4
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kosakowska EA, Stec R, Charkiewicz R,
Skoczek M and Chyczewski L: Molecular differences in the KRAS gene
mutation between a primary tumor and related metastatic sites-case
report and a literature review. Folia Histochem Cytobiol.
48:597–602. 2010.PubMed/NCBI
|
|
6
|
Ludwig JA and Weinstein JN: Biomarkers in
cancer staging, prognosis and treatment selection. Nat Rev Cancer.
5:845–856. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Radtke F and Raj K: The role of Notch in
tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer.
3:756–767. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sethi N and Kang Y: Notch signalling in
cancer progression and bone metastasis. Br J Cancer. 105:1805–1810.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pancewicz J and Nicot C: Current views on
the role of Notch signaling and the pathogenesis of human leukemia.
BMC Cancer. 11:5022011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aster JC, Pear WS and Blacklow SC: The
Varied Roles of Notch in Cancer. Annual Review of Pathology:
Mechanisms of Disease. 12:null. 2017. View Article : Google Scholar
|
|
11
|
D'Souza B, Miyamoto A and Weinmaster G:
The many facets of Notch ligands. Oncogene. 27:5148–5167. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimizu K, Chiba S, Kumano K, Hosoya N,
Takahashi T, Kanda Y, Hamada Y, Yazaki Y and Hirai H: Mouse jagged1
physically interacts with notch2 and other notch receptors.
Assessment by quantitative methods. J Biol Chem. 274:32961–32969.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu K, Moghal N and Egan SE: Notch
signaling in lung development and disease. Adv Exp Med Biol.
727:89–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Masiero M, Banham AH and Harris AL:
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front
Oncol. 4:2542014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nasarre P, Potiron V, Drabkin H and Roche
J: Guidance molecules in lung cancer. Cell Adh Migr. 4:130–145.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin MM, Ye YZ, Qian ZD and Zhang YB: Notch
signaling molecules as prognostic biomarkers for non-small cell
lung cancer. Oncol Lett. 10:3252–3260. 2015.PubMed/NCBI
|
|
17
|
Choi K, Ahn YH, Gibbons DL, Tran HT,
Creighton CJ, Girard L, Minna JD, Qin FX and Kurie JM: Distinct
biological roles for the notch ligands Jagged-1 and Jagged-2. J
Biol Chem. 284:17766–17774. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Endoh H, Tomida S, Yatabe Y, Konishi H,
Osada H, Tajima K, Kuwano H, Takahashi T and Mitsudomi T:
Prognostic model of pulmonary adenocarcinoma by expression
profiling of eight genes as determined by quantitative real-time
reverse transcriptase polymerase chain reaction. J Clin Oncol.
22:811–819. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bolkun L, Grubczak K, Schneider G, Zembko
P, Radzikowska U, Singh P, Kloczko J, Ratafczak MZ, Moniuszko M and
Eljaszewicz A: Involvement of BAFF and APRIL in resistance to
apoptosis of acute myeloid leukemia. J Cancer. 7:1979–1983. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan X, Wu H, Xu H, et al: Meta-analysis
reveals the correlation of Notch signaling with non-small cell lung
cancer progression and prognosis. Sci Rep. 5:103382015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li C, Song G, Zhang S, Wang E and Cui Z:
Wnt3a increases the metastatic potential of non-small cell lung
cancer cells in vitro in part via its upregulation of Notch3. Oncol
Rep. 33:1207–1214. 2015.PubMed/NCBI
|
|
22
|
Nguyen D, Rubinstein L, Takebe N, Miele L,
Tomaszewski JE, Ivy P, Doroshow JH and Yang SX: Notch1 phenotype
and clinical stage progression in non-small cell lung cancer. J
Hematol Oncol. 8:92015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leong KG and Karsan A: Recent insights
into the role of Notch signaling in tumorigenesis. Blood.
107:2223–2233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jonusiene V, Sasnauskiene A, Lachej N,
Kanopiene D, Dabkeviciene D, Sasnauskiene S, Kazbariene B and
Didziapetriene J: Down-regulated expression of Notch signaling
molecules in human endometrial cancer. Med Oncol. 30:4382013.
View Article : Google Scholar : PubMed/NCBI
|
